This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Affiris Ag. Active years: 2015-2017.
Location History:
- Gaenserndorf, AT (2015)
- Vienna, AT (2017)
Company Filing History:
Years Active: 2015-2017
Title: Innovations of Markus Windwarder
Introduction
Markus Windwarder is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of immunology, particularly in the development of vaccines targeting specific health conditions. With a total of two patents to his name, Windwarder is recognized for his innovative approaches to medical treatments.
Latest Patents
Windwarder's latest patents include a PCSK9 peptide combination vaccine and method of use. The first patent relates to an immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9). These fragments include at least eight consecutive amino acid residues from specific regions of the PCSK9 protein. The second patent also focuses on a vaccine or immunogenic composition that includes two fragments of PCSK9, with specific amino acid sequences designed to enhance the vaccine's efficacy. These inventions aim to provide methods of treatment for hyperlipidemia, hypercholesterolemia, and atherosclerosis through the administration of this innovative vaccine.
Career Highlights
Windwarder is currently associated with Affiris AG, a company known for its pioneering work in peptide-based vaccines. His role at Affiris AG has allowed him to further his research and development efforts in the field of immunology. His contributions have been instrumental in advancing the understanding and treatment of lipid-related disorders.
Collaborations
Windwarder has collaborated with several professionals in his field, including Sylvia Brunner and Gergana Galabova. These collaborations have fostered a productive environment for innovation and research, leading to significant advancements in vaccine development.
Conclusion
Markus Windwarder is a prominent inventor whose work in developing PCSK9 peptide combination vaccines showcases his commitment to improving health outcomes. His patents reflect a deep understanding of immunology and a dedication to addressing critical health issues.